Procter & Gamble Health Limited has announced its Q3FY26 unaudited financial results for the quarter ended December 31, 2025, showing strong revenue growth alongside margin pressures. The company reported revenue from operations of ₹3,739 million, marking a significant increase from ₹3,098 million in the corresponding quarter of the previous year, while profitability metrics faced headwinds during the reporting period.

Board Meeting and Regulatory Compliance

The Board of Directors approved the unaudited financial results at their meeting held on February 6, 2026, which commenced at 12:11 p.m. and concluded at 14:23 p.m. The results have been prepared in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and subjected to limited review by the company's statutory auditors.

Q3FY26 Financial Performance

The company's Q3FY26 results demonstrate robust top-line growth with contrasting profitability trends:

The company achieved strong revenue expansion while facing significant cost pressures that impacted overall profitability during the quarter.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Procter & Gamble Health demonstrated consistent growth momentum:

The nine-month performance shows stronger profitability growth compared to the quarterly results, indicating improved operational efficiency over the extended period.

Interim Dividend Declaration

The Board of Directors has declared an interim dividend for FY2025-26 of ₹160 per equity share, which includes a one-time special dividend of ₹50 per equity share. Key dividend details include:

The substantial dividend payout reflects the company's strong cash position and commitment to shareholder returns.

Operational Highlights

Procter & Gamble Health continues to focus on its pharmaceuticals segment as the single primary reportable business. The company has successfully transitioned its injection portfolio to contract manufacturing following the discontinuation of injection production at its Goa facility. The financial results reflect the company's strategic positioning in the healthcare sector with sustained revenue growth despite margin pressures in the current quarter.

Procter & Gamble Health Limited has revised the agenda for its upcoming board meeting, adding consideration of interim dividend declaration to the scheduled proceedings. The company communicated this update to stock exchanges on January 21, 2026.

Board Meeting Agenda Revision

The healthcare company has expanded the scope of its board meeting scheduled for February 6, 2026, to include deliberation on interim dividend declaration for Financial Year 2025-26. This addition comes as a revision to the original meeting agenda that was previously communicated to exchanges on December 26, 2025.

Regulatory Communication

The company formally notified both major Indian stock exchanges about this agenda revision. The communication was addressed to:

• BSE Limited (Scrip Code: 500126)
• National Stock Exchange of India Limited (Scrip Code: PGHL)

Company Secretary Zeal Rupani signed the official communication, which was digitally authenticated on January 21, 2026, at 12:09:05 IST. The letter specifically referenced the earlier communication dated December 26, 2025, ensuring regulatory compliance and transparency.

Corporate Governance

This revision demonstrates the company's adherence to regulatory requirements for timely disclosure of material information to shareholders and market participants. The formal notification process ensures all stakeholders are informed about potential dividend considerations well in advance of the board meeting.